Procept BioRobotics' (PRCT) estimate of its addressable market "is overly exaggerated," Spruce Point Capital Management said in a short report Thursday.
Spruce Point also said the company's claim that it will fundamentally change current benign prostatic hyperplasia protocols is "unrealistic, since there is no one-size-fits-all BPH treatment."
Procept BioRobotics didn't immediately respond to a request for comment from MT Newswires.
The company's shares were down 0.9% in recent trading.
Price: 77.64, Change: -0.67, Percent Change: -0.86
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。